Chimerix commences Phase 3 trial of brincidofovir

|About: Chimerix Inc (CMRX)|By:, SA News Editor

Chimerix (CMRX) initiates dosing in a Phase 3 study of the oral nucleotide analog lipid-conjugate brincidofovir in patients with cytomegalovirus infection.

Existing antiviral therapies for the infection (which affects hematopoietic cell transplant recipients) carry the risk of "significant hematologic and renal toxicities."

No approved therapy for the prevention of the infection in hematopoietic cell transplant recipients exists. (PR)